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Abstract
Components of the ocular surface synergistically contribute to maintaining and protecting a smooth refractive
layer to facilitate the optimal transmission of light. At the air–water interface, the tear film lipid layer (TFLL), a
mixture of lipids and proteins, plays a key role in tear surface tension and is important for the physiological
hydration of the ocular surface and for ocular homeostasis. Alterations in tear fluid rheology, differences in lipid
composition, or downregulation of specific tear proteins are found in most types of ocular surface disease,
including dry eye disease (DED). Artificial tears have long been a first line of treatment in DED and aim to
replace or supplement tears. More recently, lipid-containing eye drops have been developed to more closely
mimic the combination of aqueous and lipid layers of the TFLL. Over the last 2 decades, our understanding of
the nature and importance of lipids in the tear film in health and disease has increased substantially. The aim of
this article is to provide a brief overview of our current understanding of tear film properties and review the
effectiveness of lipid-based products in the treatment of DED. Liposome lid sprays, emulsion eye drops, and
other lipid-containing formulations are discussed.
Keywords: tear film, lipid layer, liposome, emulsion, ocular surface disease
Introduction
Over the last 2 decades, our understanding of thenature and importance of lipids in the tear film in health
and disease has increased substantially. In this review, we
review the effectiveness of lipid-based products in the treat-
ment of dry eye disease (DED), including liposome lid sprays,
emulsion eye drops, and other lipid-containing formulations.
The ocular surface is a critical element of vision that
includes the cornea, conjunctiva, lacrimal gland, accessory
lacrimal glands, meibomian glands, tears, connective tis-
sues, eyelashes and their associated glands of Moll and Zeis,
and the nasolacrimal duct.1 Each of these elements has a
specific role; is controlled by nervous, endocrine, circulatory,
and inflammatory systems; and synergistically contributes
to maintaining and protecting the smooth refractive sur-
face and transparency of the cornea for optimal transmission
of light.1,2 Lacrimal glands, accessory lacrimal glands, and
meibomian glands secrete aqueous fluid, proteins, and lipids
to form the tear film that hydrates the cornea.1,3
The tear film was first described by Wolff et al. as 3 dis-
tinct layers: the outer lipid layer, the middle aqueous layer,
and the inner mucin layer, which interacts with the corneal
epithelial surface.4,5 The aqueous layer contains electrolytes,
proteins/peptides, and small-molecule metabolites.6 Mucins
present in the deepest layer of the tear film, such as glyco-
calyx, mucin, and membrane-associated mucins, are released
by goblet cells and maintain the wettability of the corneal
surface.5 To date, several hundred tear proteins have been
identified, including lysozyme and lactoferrin, which have
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antibacterial properties to protect the ocular surface from
pathogens,3,6 and lipocalin, which can intercalate with tear
lipids to form an additional biphasic lipid layer not described
in Wolff’s original 3-layer model.7,8
At the air–water interface, the outer layer, also called the
tear film lipid layer (TFLL), is primarily composed of lipids
that prevent water evaporation and ocular surface dewetting
and provide a smooth optical surface for the cornea.5,9–11
More recently, additional roles of the TFLL have been de-
scribed, including maintenance of ocular homeostasis, op-
timization of tear spreading patterns, direction of aqueous
flow to the puncta, and prevention of film overflow during
blinking.11,12 Lipids are released by the meibomian glands
located in the eyelids, both during blinking and under the
control of vasoactive intestinal polypeptide; the composition
of these lipids may be affected by ATP stimulation of pur-
inergic receptors expressed on the meibomian glands.7
The TFLL is composed primarily of nonpolar lipids (wax
esters and cholesterol esters), but small amounts of polar
lipids (phospholipids) have also been found in the TFLL
from human and laboratory animals. The hydrophilic polar
lipids act as an interface between the aqueous layer and the
nonpolar lipid surface layer.7,13,14 The wax ester in the
nonpolar surface layer is thought to delay evaporation,15,16
but its exact role is controversial, as recent evaporation
studies and rheology have questioned the ability of wax
esters to prevent tear evaporation in vivo.15,17
The TFLL also includes fatty acids and fatty alcohols (in-
cluding acetic acid) that act as surfactants to stabilize the
lipid–water mixture.7,11 The fatty acid–lysophospholipid bal-
ance is governed by the amounts of cholesterol and/or epi-
cholesterol, glycerols, and lysophospholipids in the TFLL.
More recently, amphiphilic lipids, such as cholesteryl sulfate,
O-acyl-o-hydroxy fatty acids, various sphingolipids, and
phospholipids, were found in the human TFLL.18 The lipid
and protein components of the TFLL play a key role in tear
surface tension and are important for the physiological hy-
dration of the ocular surface and ocular homeostasis.5,11,12,14
Pathophysiology and Treatment
of Ocular Surface Disease
The ocular surface is affected by medications (eg, anti-
glaucoma drugs), contact lens wear, and ocular surface dis-
eases6,19 such as DED, blepharitis, and ocular allergies. DED
can be classified into aqueous tear deficient, evaporative,
and mixed forms depending on its etiology.20 Evaporative
DED, typically caused by meibomian gland dysfunction
(MGD), is attributed to a qualitative and/or quantitative de-
fect of the lipid layer that leads to tear film instability.20
Patients lacking a visible lipid layer, or those with a non-
confluent TFLL, have a 4-fold higher rate of tear film evap-
oration than those with a continuous lipid layer regardless
of lipid layer thickness.21 Alterations in tear fluid rheol-
ogy or lipid composition or the downregulation of specific
tear proteins are found in most types of DED; for example,
alterations in the phospholipid content, potentially due to
bacterial lipase–mediated hydrolysis of phospholipids into
lysophospholipids, can lead to DED7,11,18,22
The first line of therapy for DED is aimed at relieving
patient symptoms.23 In MGD, gland obstructions can be
cleared by warm compresses and self-administered lid
massages, by thermal pulsation treatment (eg, LipiFlow) or
by intraductal meibomian gland probing.24,25 In DED, arti-
ficial tears are used to replace or supplement tears.26
Lipid-containing eye drops have been proposed as a step
closer to natural tears because they more closely mimic the
aqueous and lipid layers.27 Such lipid-based agents would
be expected to benefit patients with DED (particularly the
evaporative form of DED), as well as related ocular surface
diseases (eg, diseases of allergic/infectious origin such as
allergic rhinoconjunctivitis, or other conditions such as con-
tact lens discomfort). In tear film-oriented therapy (TFOT),
treatment is tailored based on analysis of tear film dynamics,
which includes identification of the damaged ocular sur-
face or tear film component in the patient with DED.28
Because the TFOT tailors treatment to a specific component
of DED pathophysiology, TFOT is becoming a recommended
treatment paradigm in Japan.28
Additionally, topical therapeutic options are available to
individually treat each layer of the ocular surface in patients
with DED. Randomized clinical trials of water-based eye
drops containing sodium hyaluronate, carboxymethylcel-
lulose, or carbomers have demonstrated improvements in
DED symptoms, corneal wound healing, tear osmolarity, and
tear film break-up time.29–32 However, as the lacrimal fluid
also contains a combination of lipids, and given that changes
in tear lipid composition can lead to DED, lipid-containing
eye drops have emerged as an alternative therapy to water-
based-only artificial tears.20,22,33
Lipid-based products are designed to mimic the tear film
and provide long-lasting lubrication to the eye surface, but it
remains uncertain if they can fully replenish the TFLL.15,22
A recent publication by McCann et al. reported that lipid-
based eye drops decreased tear film osmolarity and improved
tear film stability and corneal staining more effectively than
water-based eye drops containing sodium hyaluronate and
hydroxypropyl methylcellulose in patients with mild-to-
moderate evaporative DED.34 Furthermore, a systematic lit-
erature review of randomized controlled studies revealed
strong clinical evidence for the effective use of lipid-
containing lubricants in the treatment of DED.35 Of note, the
U.S. Food and Drug Administration Code of Federal Reg-
ulations Title 21 part 349 recommends that lipids can be used
as ‘‘emollients’’ (or ‘‘lubricants’’) in ophthalmic products (eg,
lanolin, light mineral oil, mineral oil, paraffin, petrolatum,
white ointment, white wax, and yellow wax) indicated for
‘‘the temporary relief of burning and irritation due to dryness
of the eye’’ or ‘‘the use as a lubricant to prevent further
irritation or to relieve dryness of the eye.’’36
Lipid-Based Therapies
Liposomes
Liposomes are bilayered lipid vesicles, structurally clas-
sified as small unilamellar or multilamellar, with a parti-
cle size of 10 nm to 1 mm, although they can sometimes be
larger (Fig. 1, 1a, b).37 Biodegradable and biocompatible
in nature, liposomes are mainly composed of phosphati-
dylcholines (phospholipids) and other constituents such as
cholesterol and lipid-conjugated polymers. For therapeutic
use they are prepared by thin-film hydration methods fol-
lowed by 5-cycle sonication, which results in a more uni-
form particle size, ranging from 0.1 to 1 mm in diameter, that
is ideal for drug loading.37–39
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Liposomal formulations were first proposed as drug de-
livery vehicles in ophthalmology to enhance ocular drug
penetration. Drug-loaded liposomal eye drops (eg, cipro-
floxacin, acetazolamide, and tacrolimus) have been tested
over the last decade to treat various ocular disorders of both
the anterior and posterior segments, including infections,
DED, corneal transplant rejection, glaucoma, and uve-
itis.37,40 In addition, nondrug-loaded liposomal lid sprays
were more recently introduced for the treatment of DED
with the aim of renewing the TFLL.40–42
Several products in this category, such as Tears Again
(Optima Pharmazeutische GmbH; also marketed as Optrex
ActiMist and Eye Logic Liposomal Spray), Clarimist, and
Vyseo Sensitive are made of soy lecithin, which is mainly
composed of the phospholipid phosphatidylcholine.8 Other
components include lipophilic vitamins with potential ocular-
protective properties (eg, vitamins A and E), ethanol, water,
and sodium chloride. Liposomal sprays are simply applied
onto the outside of the lids, and the polar phospholipids dif-
fuse from the lid surface to the tear film and thus supplement
the TFLL. This provides lubrication, helps prevent tear film
evaporation, and alleviates DED symptoms.37,42
The tolerability of liposomal preparations is dictated by
their surface tension, pH, osmolarity, and viscosity.38 In
one study, a nondrug-loaded liposomal formulation con-
taining phosphatidylcholine, cholesterol, and vitamin E
achieved values for each of these parameters close to the
physiological range (surface tension &30 mN/m, pH
6.45 – 0.09, osmolarity 289.43 – 3.28 mOsm, and viscosity
1.82 – 0.02 mPa  s) and was well tolerated in a rabbit
model when administered every 30 min for 6 h (Table 1).38
The formulation induced minimal corneal and conjunctival
cytotoxicity, with a cell viability greater than 95% after
15 min of exposure.38 In a rabbit model of dry eye treated
with liposome-encapsulated tetracycline, tear break-up
time and Schirmer’s test values were significantly im-
proved and associated with a restoration of corneal and
conjunctival cytological architecture after daily liposome
administration for 7 days.43
Drug-loaded liposomes exhibit improved tolerance, drug
delivery and penetration, and corneal healing in comparison
with other ophthalmic drug delivery vehicles typically used
in rabbit models.44–46 Chitosan-coated liposomes have been
developed to further enhance drug permeation and prolong
drug retention rates. These benefits may be attributable in
part to the positive charge of the chitosan molecules, which
can bind to the negatively charged mucus film and lipid
membrane of epithelium cells. Chitosan-coated liposomes
are well tolerated in vivo in rabbits and in vitro in rabbit
conjunctival epithelial cells.47
Nondrug-loaded liposomes also demonstrate improved
clinical efficacy (Table 2). A multicenter, double-masked
clinical study showed that Optrex ActiMist, also marketed as
Tears Again and Eye Logic Liposomal Spray, significantly
improved DED symptoms and tear film stability, which is
essential for limiting the evaporation of the TFLL.9,48 The
delivery of phospholipid liposomes to the tear film by ap-
plying a liposomal spray (Tears Again) to the surface of the
closed eyelid has been shown to improve ocular comfort,
lipid layer thickness, and tear film stability in healthy patients
versus a saline spray.42 Ocular comfort scores also improved
with the same product, as observed in a randomized clinical
study of healthy and self-diagnosed dry eye patients using
the Chalmers 5-item questionnaire; a similar reduction in the
Strehl ratio of higher-order aberrations was observed in both
populations.49
In an open-label, observational study in patients with
seasonal allergic rhinoconjunctivitis, Tears Again in com-
bination with a liposomal nasal spray containing dex-
panthenol (LipoNasal) demonstrated noninferior efficacy
when compared with the standard cromoglycate therapy.
Liposomal spray treatment was associated with a favorable
tolerability profile in terms of eye irritation and vision dis-
turbances over a 7-day treatment period (2–3 times per eye
per day).41
The liposomal treatment Lacrisek ofta mono (Bios Ita-
lia), which incorporates hydrogenated phospholipids, vitamin
A palmitate, and vitamin E, was compared with Artelac
Rebalance, a water-based tear substitute containing poly-
ethylene glycol and hyaluronic acid, in a single-instillation
study of patients with evaporative dry eye. Improvements in
interblink interval, tear break-up time (TBUT), and tear film
evaporation time were superior for Lacrisek ofta mono from
10 min after instillation to the end of the 60-min assessment
period.50 This preclinical and clinical evidence demon-
strates that liposomal eye drops and sprays are well tolerated
and efficacious in improving DED symptoms.
FIG. 1. Schematic representations of various lipid-based
products, including unilamellar liposomes (1a), multi-
lamellar liposomes (1b), anionic emulsions (2a), cationic
emulsions (2b), SLNs (3a), NLCs (3b). SLN, solid lipid
nanoparticle; NLC, nanostructured lipid carrier.
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Emulsions
To better mimic and supplement the tear film, which is
also water-based,9,51 emulsions containing both water and
lipid have been developed. Oil-in-water emulsions consist of
oily droplets stabilized by surfactants or emulsifiers dis-
persed in an aqueous medium (Fig. 1).52 For pharmaceuti-
cal topical ophthalmic instillation, most emulsions contain
submicron-sized particles prepared with oils (eg, sesame oil,
castor oil, soya oil, paraffin oil, paraffin light, lanolin,
Vaseline [Unilever], corn oil, glycerin monostearate, me-
dium chain monoglycerides, and medium chain triglycerides)
and emulsifiers (eg, phospholipids [Lipoid], polysorbate 80
(Tween 80), Cremophor RH, poloxamer 407, poloxamer
188, Miranol C2M, and tyloxapol) that are well tolerated at
the concentrations used in these formulations.53 Emulsions
can be anionic (negatively charged) or cationic (positively
charged) depending on the components added to the for-
mulation during the emulsion process.53 Oil-in-water emul-
sions are often used as topical ocular drug delivery carriers
to enhance membrane permeability and cellular uptake of
lipophilic molecules.51–55
Anionic emulsions. Anionic emulsions are commer-
cially available in some countries and include Optive Plus
(Allergan), Systane Balance (Alcon), Soothe XP (Bausch
and Lomb), Emustil (SIFI), Refresh Endura (Allergan),
Restasis (Allergan), Durezol (Alcon), Aquarest/Liposic
(Bausch and Lomb), Soft Santear (Santen), and Lipimix
(Pharma Stulln). Like liposomes, anionic emulsions have
demonstrated a favorable tolerability profile, in that they
decrease eye irritation and vision disturbances. For instance,
an anionic lipid emulsion of Miglyol 840 oil (IOI Oleo
GmbH) and lecithin56 tested in rabbits was well tolerated
and had a low ocular lesion index after topical instillation
(30 mL) every 30 min for 6 h (Tables 1 and 2).53
In terms of efficacy, Emustil (an anionic emulsion con-
taining natural phospholipids) significantly improved tear
volume and reduced corneal damage when applied 4 times a
day for 7 days either as a monotherapy or in combination
with sodium hyaluronate in a mouse model of dry eye.57
Artificial tears containing sodium hyaluronate and castor oil
tested in a porcine short-term dry eye model also had a
protective effect against corneal desiccation.58 Similarly,
coating emulsions with chitosan was shown to prolong the
residence time of the emulsion in the tear fluid of rabbits.59
Studies evaluating the efficacy of commercially avail-
able anionic emulsions to improve dry eye symptoms and
lipid tear film stability in human patients have shown pos-
itive results (Table 2). Of note, a pilot study in 5 asymp-
tomatic and 10 symptomatic, aqueous tear-deficient dry eye
patients who were given Refresh Endura (castor oil with
1% glycerin and 1% polysorbate 80) once a day in one eye
and saline as control in the other eye demonstrated lipid
tear film restructuring after a single instillation of treat-
ment.60 Another pilot study in normal and dry eye patients
reported increased tear film lipid thickness, tear film break-
up time, and comfort scores up to 1 h postinstillation of
Refresh Endura, as well as overall symptom improvement
for up to 4 h postinstillation in patients with symptomatic
dry eye.61
In patients with mild-to-moderate dry eye treated with an
anionic emulsion of 1.25% castor oil or 0.32% HPMC
monotherapy 3 times daily for 30 days, both treatments
resulted in decreased tear evaporation rates, but only the
emulsion improved lipid layer structure at day 30.62 A
multicenter observational study evaluated 1,209 dry eye
patients for 4 weeks after starting or switching to Optive
Plus, which contains carboxymethylcellulose, glycerol, L-
carnitine, erythritol, and a polysorbate 80 vessel that de-
livers pure castor oil to the tear film. The results indicated
improvements in dry eye severity, tear break-up time, and
Schirmer’s test scores relative to baseline.63
Emustil administered 4 times daily for 90 days to evapora-
tive dry eye patients improved tear stability and decreased tear
osmolarity and corneal staining to a greater extent than 2 other
comparators, Lubristil 0.15% sodium hyaluronate unidose
(SIFI) and Dacriosol 0.3% hydroxypropyl methylcellulose
unidose (Alcon).34 However, a 3-month clinical study com-
paring Emustil to Cationorm (Santen) or Optive (Allergan)
in patients with moderate dry eye reported no significant im-
provement in tear film break-up time or fluorescein staining
following treatment with Emustil.64
In habitual contact lens wearers experiencing symptoms
of contact lens discomfort, Systane Balance (dimyristoyl
phosphatidylglycerol, hydroxypropyl-guar, mineral oil,
polyoxyl 40 stearate) improved lens comfort, wearing time,
lid wiper epitheliopathy, and corneal staining when admin-
istered up to 4 times per day versus a nonlipid contact lens
rewetting drop.65 Systane Balance moderately improved
corneal staining and tear film break-up time in patients with
dry eye associated with MGD, and approximately 60% of
patients switching to Systane Balance preferred it to their
usual lubricant eye drops or artificial tears.66
A randomized, parallel-group, controlled, investigator-
masked comparison study in patients with lipid-deficient dry
eye treated with Systane Balance or saline 4 times daily for
4 weeks showed that Systane Balance restored tear film
stability, improved ocular surface staining, and improved
meibomian gland functionality.67 In addition, dry eye pa-
tients treated with either Refresh Dry Eye Therapy (castor
oil with 1% glycerin and 1% polysorbate 80) or Soothe
(light mineral oil 1.0% and mineral oil 4.5%) demonstrated
increased lipid layer thickness, but treatment with Soothe
resulted in greater improvements in lipid layer thickness.68
Castor oil eye drops, another investigational anionic emul-
sion product, have been well tolerated and have effectively
improved symptom scores, tear interference grade, tear
evaporation, rose bengal staining, tear film break-up time,
and orifice obstruction scores in MGD patients when ad-
ministered 6 times daily for 2 weeks.69
Carbomer-based lipid artificial tears improved both dry
eye symptoms and signs, including Schirmer’s test values
and tear film break-up time, similar to or better than hy-
droxypropyl (HP)-guar gel after 2 and 4 weeks of treat-
ment.70 Furthermore, meibomian gland secretion improved
to a greater extent after 3 months of combination therapy
with anionic emulsions, lid hygiene, and omega-3 nutri-
tional supplementation versus treatment with only warm and
wet compresses in patients with lipid-deficient dry eye.71
In the published clinical trials reviewed herein, the
most common adverse event related to the application of
anionic emulsions observed between studies was blurred
vision.60,62,63,66 However, in some studies, adverse events
were not reported.34,61,67 This underlines the safety of their
use as ophthalmic drug delivery systems.
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Cationic emulsions. Cationic emulsions are biphasic for-
mulations of positively charged oil nanodroplets (oily phase)
dispersed in water (the continuous phase) (Fig. 1, 2b).72,73
The positively charged nanodroplets within cationic emul-
sions interact with the negatively charged ocular surface
mucins and cell membranes.51,72,74 This bioadhesive property
prolongs eye drop residence time and improves the bio-
availability of lipophilic drug molecules delivered through
these emulsions.53,72,73 The physicochemical parameters of
a cationic emulsion influence its stability and physiological
biocompatibility; for instance, the optimal properties of na-
nodroplets include a size less than 200 nm, a pH between 5
and 7, and an osmolarity of approximately 270 mOsm/kg.72
Choosing the appropriate cationic agent is also essen-
tial. Several agents such as stearylamine, oleylamine,
poly(ethylenimine), poly(l-lysine), 1,2-di-(9Z-octadecenoyl)-
sn-glycero-3-phosphoethanolamine (DOPE), 1,2-di-(9Z-
octadecenoyl)-3-trimethylammoniumpropane (DOTAP), and
benzalkonium chloride (BAK) derivatives are available, but
their use as cationic agents is limited by toxicity, stability,
or regulatory issues. These limitations encourage the de-
velopment of unpreserved ophthalmic preparations.75 Ce-
talkonium chloride (CKC), a C16 BAK derivative, is the
preferred cationic agent in cationic emulsions because it has
superior lipophilicity that limits it to the oily phase of the
oil-in-water nanoemulsion, thereby minimizing toxicity.72
In emulsions, quaternary ammoniums, such as CKC, which
are not found in the aqueous phase, are solely used as cationic
agents and do not exert detergent activity or preservative
action.72,73,76,77 Cationic emulsions also provide improved
spreading coefficients on the cornea and conjunctiva versus
conventional eye drops and anionic emulsions, thereby im-
proving ocular surface wettability. This has been demon-
strated by Cationorm (Santen; also known as Retaine MGD
in the US; OCuSOFT), a preservative-free cationic emul-
sion, in contact angle and surface tension studies73 (Table 1).
Additionally, a cationic emulsion containing a combination of
phospholipids (Lipoid E 80), poloxamer 188 (Pluronics F68),
and stearylamine as emulsifiers had a favorable tolerability
profile when administered (40 single-drop instillations per
day for 5 days) to rabbit eyes, despite the potential of stear-
ylamine causing ocular irritation.53
In additional preclinical studies, human corneal epithelial
cells (HCE-2 cells) were incubated with Cationorm or Sys-
tane, each diluted 1:10, for up to 30 min. The dilution was
used to mimic in vivo conditions, whereas the 30-min expo-
sure time was longer than would be realistically expected
in vivo. Neither Cationorm nor Systane were associated with
any significant change in HCE-2 cell morphology or viability,
and reduced inflammatory responses were elicited versus
BAK, suggesting that both products would be better options
than BAK for long-term use in DED.78 Moreover, cationic
emulsions utilizing BAK (0.02%) and CKC (0.002%) as
cationic agents were less toxic than BAK/CKC aqueous so-
lutions at the same concentrations in a severe eye irritation
rabbit model (15 instillations at 5-min intervals).79 In this
same study, a CKC-containing cationic emulsion caused a
similar degree of redness, chemosis, and conjunctiva secre-
tions as the phosphate-buffered saline control.79
The tolerability of cationic emulsions was also confirmed
with a latanoprost-loaded emulsion in HCE cells, in a rat
corneal wound model, and in a rabbit ocular tolerance mod-
el.80,81 Cationic lipids have also demonstrated the potential
for exhibiting both antimicrobial and anti-inflammatory
properties.82 Glucocorticoid-linked polyamine cationic lipids
induce glucocorticoid receptor translocation and display
bactericidal activity against several strains of Pseudomonas
aeruginosa.82 Cationorm reduced stromal inflammatory cell
infiltration as determined by in vivo confocal microscopy.83
In patients with mild-to-moderate dry eye, instillation of
Cationorm (1 drop per eye 4 times daily for 28 days) im-
proved tear film break-up time as early as Day 7 and was
well tolerated by patients (Table 2).84 In this same study,
a significant improvement in lissamine green staining was
observed after 28 days of treatment, suggesting that this
cationic emulsion reinforces the lipid layer, minimizes evap-
oration, and stabilizes the tear film to protect the ocular
surface.84 In another clinical trial of Cationorm and
Vismed (TRB Chemedica) in patients with moderate-to-
severe dry eye, although both eye drops showed similar
safety profiles and efficacy in terms of improvements in
objective signs of dry eye, Cationorm was superior in im-
proving the global symptoms score of ocular discomfort.85
These cationic emulsions are lipid-based drug nanocarriers
and promising new vehicles for ocular drug delivery, for
example, delivery of ciclosporin, to treat various ocular
surface diseases, including dry eye.73,86 Although ciclosporin
has potent anti-inflammatory properties and is an established
second-line treatment option for dry eye, ocular delivery of
ciclosporin is challenging because it is highly lipophilic.23,73
Nonetheless, ocular delivery of ciclosporin is enhanced by
encapsulating it in a cationic emulsion, increasing its bio-
availability and corneal penetration.51,52,87,88
In the published clinical trials reviewed here, the most
common adverse events related to the application of cationic
emulsions were eye pain, instillation site pain, or irritation,
and these events were mostly mild in severity.84–86 These
data show the use of cationic emulsions as ophthalmic drug
delivery systems is well tolerated.
Other Lipid-Based Carriers
Other lipid-based products, including sterile ophthalmic
ointments, are used as more conventional lubricants.23 These
products do not contain water and thus do not directly
moisturize the ocular surface or replenish tears, but they
can potentially replenish waxes or oils through delivery of
white petrolatum, mineral oil, or lanolin.89 When used as
drug delivery vehicles (eg, for ketorolac, tacrolimus, ciclo-
sporin, gefarnate, etc.), ophthalmic ointments prolong pre-
corneal residence time and sustain drug availability.89–91
These types of lubricants have been used for the treatment of
DED, but their high viscosity often leads to blurred vision upon
application.23,92 However, when used at bedtime, ophthalmic
ointments provide sustained effect without this uncomfort-
able side effect.89 Pure oily solutions (eg, castor oil, olive
oil, corn oil, etc.) are often used in hospital-compounded
ophthalmic preparations of various drugs, including ciclo-
sporin.93,94 However, the role of their intrinsic properties in
supplementing or stabilizing the TFLL is unknown.
There are a number of other lipid-based formulations of
drug carriers aside from ointments (Fig. 1, 3a, b). Poly-
aphrons are lipid-containing carriers with oil droplets in the
micron range encapsulated within a water film95 that are
being investigated as vehicles for ciclosporin delivery to treat
DED (EudraCT number: 2015-000937-54).96 Ciclosporin has
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also been successfully loaded into biocompatible semi-
fluorinated alkanes, and in an ex vivo corneal model, this
carrier provided more effective diffusion of ciclosporin
through the corneal barrier than Restasis (Table 1).97 Re-
cently, another semifluorinated alkane-based drug delivery
carrier (NovaTears [perfluorohexyloctane]; Novaliq GmbH)
has been shown to effectively stabilize the tear film, reduce
corneal staining, and improve dry eye symptoms in patients
with mild-to-moderate dry eye without impacting visual
acuity (Table 2).98
Lipid nanocarriers are a class of colloids that includes
nanostructured lipid carriers (NLCs), solid lipid nano-
particles (SLNs), and lipid–drug conjugates. Recent studies
show that NLCs may be useful for ocular drug delivery
given their potential to improve drug penetration owing to
increased bioadhesion to the ocular epithelium.99–101 SLNs
are modified nanoemulsions that substitute the liquid oil
phase with a solid lipid core and are typically composed of
physiological lipid mixtures of high melting point mono-,
di-, and triglycerides and waxes stabilized by surfactants.102
Like nanoemulsions, SLNs are biocompatible, physically
stable, and capable of carrying drugs, such as ciclosporin
and other anti-inflammatory drugs, for the treatment of
ocular surface diseases.99,100,102 SLNs are internalized by
ocular tissues and may improve the bioavailability of en-
capsulated drugs;100 however, their benefit in supplementing
the tear film or the compatibility of their high melting point
lipids with the TFLL have yet to be explored.
In the published clinical trials reviewed above, the in-
cidence of adverse events following application of semi-
fluorinated alkane drops occurred in few (<5) patients, and
there were no serious adverse events reported. However,
some patients showed signs of mild-to-moderate hyper-
sensitivity to semifluorinated alkane drops.98 Overall, data
suggest that oily solutions, SLNs, and NLCs are generally
well tolerated.
Conclusion
Lipid-based therapies (liposomal sprays and emulsion eye
drops) are an attractive alternative to water-based artificial
tears because they more closely mimic the composition of
the tear film. Lipid-based therapies not only relieve patient
symptoms immediately after topical administration, but
may also directly improve the lipid tear film structure and
thickness component in ocular surface disease, resulting in
enhanced tear film stability. Furthermore, their composition
and rheology may benefit tear film properties and tear film
stability. Components in the aqueous phase of the emulsions
(eg, osmoprotectants such as glycerin, emulsifiers, or poly-
mers) may also provide additional effect on the ocular surface
(eg, lubrication, osmoprotection). Oil-in-water emulsions
reduce the signs and symptoms of all types of dry eye,35,62
but are particularly recommended for lipid-deficient dry
eye patients.63 Cationic emulsions provide optimal ocular
spreading and residence time with ocular surface benefits to
improve DED, especially in MGD patients.73,84
The favorable tolerability profile and efficacy of lipid-
based therapies in improving both signs and symptoms of
dry eye make them a promising therapeutic option in the
management of DED.37,73,87,103 Lipid-based therapies also
have the potential to be combined with conventional ocu-
lar surface disease therapies such as lid wipes, omega-3
supplementation, ciclosporin, or diquafosol for disease and
symptom management.71,104,105 Finally, cationic lipids pos-
sess anti-inflammatory properties,82,83,106 providing a new
perspective of lipid-based therapy for ocular surface in-
flammation and disease.107
Improvements in drug delivery mechanisms may provide
patients with a longer duration of symptom relief, improve
adherence and compliance, and ultimately improve patient
satisfaction. In particular, nanotechnologies such as NLCs
and SLNs offer the possibility of a high degree of control
over pharmacokinetic variables such as residence time,
penetration of ocular tissues, solubility, and rate of release.99
The choice and composition of the lipids added to arti-
ficial tears, in terms of their polarity and quantity, should be
further studied to understand their impact on and potential
to improve the TFLL and dry eye symptoms and disease
progression. An interdisciplinary approach involving lipi-
domics, surface chemistry, molecular dynamics, lipid aber-
rations, rheology, and computational biophysics may address
this need.22,108–112
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